SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a
SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “abiraterone-like” agent in comparison with placebo — though radiographic progression-free survival was improved. This finding at the 2014 ASCO Genitourinary Cancers Symposium was presented by Robert Dreicer MD from the Taussig Cancer Institute, Cleveland Clinic, in Cleveland Ohio. He discussed the clinical implications and noted that research is making progress in this challenging clinical situation.
CONTACT:
Dr. Robert Dreicer MD
Taussig Cancer Institute
9500 Euclid Avenue/ R35
Cleveland Clinic, Cleveland
OHIO 44195
USA
SOURCE: ASCO Genitourinary Cancers Symposium 2014 San Francisco
e.g. Abstract number: 7^
Abstract Title:
Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).
LINK:
Web link: http://meetinglibrary.asco.org/content/124293-142
Tags
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study
Standing ovation at ASCO for RASolute 302 Study
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer